Home
| Log in or Sign Up for full access
| Tracked Organizations
| Recent Tracked Activities
Recent Activities
Activities between Nov. 15, 2024, 8:09 p.m. and Nov. 22, 2024, 8:09 p.m.
from: Healthcare Private Equity Firm.
Click on a document link to see the original source document.
Click on the name of an organization to see more organization linkages and timelines.
Document Date: Nov. 20, 2024, 2 p.m. / Source: PR Newswire
Activity Class: CorporateFinanceActivity
/ Type: Investment
Target:
Document Extract: SEATTLE, Nov. 20, 2024 /PRNewswire/ - Frazier Healthcare Partners (Frazier) , a dedicated healthcare private equity firm, today announced the close of its latest flagship fund, Frazier Healthcare Growth Buyout Fund XI, L.P. (FHGB XI) .
Document Source: https://www.prnewswire.com/news-releases/frazier-healthcare-partners-closes-oversubscribed-2-3-billion-11th-growth-buyout-fund-in-six-months-302310924.html
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 3:18 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership:
- Sepragen Corporation
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology
- Sepragen Corporation
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology
- Shimadzu Corporation
/ Industry: Biopharmaceutical And Biotech Industry, Healthcare Private Equity Firm and 1 more
- Shimadzu Corporation
/ Industry: Biopharmaceutical And Biotech Industry, Healthcare Private Equity Firm and 1 more
Document Extract: This process relies on large scale chromatography systems and consumables such as columns and resins. The "bioprocess chromatography business" has been experiencing rapid growth, driven by the expansion of the biopharmaceutical market. The average annual growth rate is over 10 %, though challenges remain with manufacturing scaling of purification steps and in analysis of critical quality parameters of target compounds, which are potential bottlenecks to ensuring a growing supply of biopharmaceuticals. Moving forward, Shimadzu will create synergies between its analytical technologies and Sepragen's biomanufacturing technologies, aiming to establish robust methods for analysis and evaluation within the purification process. The collaboration between Sepragen and Shimadzu will accelerate the deployment of new products and technologies into society, contributing to the rapid development and stable manufacturing of biopharmaceuticals.
Document Source: https://www.businesswire.com/news/home/20241119333334/en/Shimadzu-Invests-in-Sepragen-Corporation
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, noon / Source: PR Newswire
Activity Class: RoleActivity
/ Type: Starting
/ Region: People’s Republic of China
Role:
Person:
Organization:
- Cango Inc
/ Industry: Automotive And Technology, Automotive Retail And Services
- Cango Inc
/ Industry: Automotive And Technology, Automotive Retail And Services
Document Extract: SHANGHAI, Nov. 18, 2024 /PRNewswire/ - Cango Inc. (NYSE: CANG) ("Cango" or the "Company") , a leading automotive transaction service platform in China, today announced the appointment of MaloneBailey, LLP ("MaloneBailey") as the Company's independent registered public accounting firm for the year ending December 31, 2024 and on the effectiveness of the Company's internal control over financial reporting as of December 31, 2024, effective on November 18, 2024.
Document Source: https://www.prnewswire.com/news-releases/cango-inc-announces-change-of-independent-registered-public-accounting-firm-302308268.html
(archive.org page /
archive.org listing)
Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.
Treat sameAsNameOnly relationship as same? Yes
(Turn Off)
Site Stats
| About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License.
Please send an email if you need a non-share-alike license and/or you need API access.